Andrea Boutros, Assistant Professor at University of Genoa, shared on X:
“Five-year outcomes of neoadjuvant therapy in melanoma from the INMC, out in Nature Medicine
- 1,038 patients
- 26 sites
- trial and real-world
With a major pathological response to neoadjuvant ICI, 5-year OS was about 98%”
Read the full article:
Article: Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Authors: Georgina V. Long, Inês Pires da Silva, Kristen A. Perry, Jurriaan Romano, Serigne N. Lo, Piyush Grover, Paolo A. Ascierto, Rodabe N. Amaria, Tina J. Hieken, Caroline Robert, Lucie Heinzerling, Shahneen Sandhu, Milton Barros, Tara C. Mitchell, Zeynep Eroglu, Igor V. Samoylenko, Lukas Flatz, Céleste Lebbé, Douglas B. Johnson, Piotr Rutkowski, Eva Muñoz-Couselo, Omid Hamid, Claudia Trojaniello, Domenico Mallardo, Matthew S. Block, Naima Hammoudi, Naima Benannoune,
Dirk Tomsitz, Yang Wang, Cigdem Dinckal, Angelina Kuzmenko, Andrea Forschner, Matteo S. Carlino, Mathilde Jalving, Michael A. Postow, P. Francesco Ferrucci, Ellen Kapiteijn, Astrid A. M. van der Veldt, Karijn P. M. Suijkerbuijk, Laetitia da Meda, Hannah Burnette, Anna Czarnekca, Inderjit Mehmi, Geke Hospers, Sarah Lochrin, Alexander C. J. van Akkooi, Hussein A. Tawbi, Elizabeth M. Burton, Michael T. Tetzlaff, Bart A. van de Wiel, Robert V. Rawson, Christian U. Blank, Alexander M. Menzies
You may also be interested in:
INMC Analysis: Can Pathological Response Guide Treatment in Melanoma?
